HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hemorrhage

Bleeding or escape of blood from a vessel.
Also Known As:
Bleeding; Hemorrhages
Networked: 140190 relevant articles (8525 outcomes, 14049 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Stroke (Strokes)
2. Wounds and Injuries (Trauma)
3. Thrombosis (Thrombus)
4. Hemorrhage
5. Neoplasms (Cancer)

Experts

1. Lip, Gregory Y H: 438 articles (11/2022 - 01/2002)
2. Mehran, Roxana: 289 articles (12/2022 - 02/2004)
3. Bhatt, Deepak L: 252 articles (12/2022 - 06/2002)
4. Stone, Gregg W: 222 articles (11/2022 - 07/2003)
5. Valgimigli, Marco: 179 articles (12/2022 - 10/2009)
6. Wallentin, Lars: 178 articles (01/2022 - 05/2002)
7. Angiolillo, Dominick J: 158 articles (12/2022 - 08/2008)
8. Eikelboom, John W: 158 articles (11/2022 - 01/2002)
9. Mahaffey, Kenneth W: 149 articles (03/2022 - 12/2002)
10. Rao, Sunil V: 141 articles (12/2022 - 10/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hemorrhage:
1. Hemostatics (Antihemorrhagics)IBA
2. AnticoagulantsIBA
3. Warfarin (Coumadin)FDA LinkGeneric
4. Heparin (Liquaemin)FDA LinkGeneric
5. recombinant FVIIa (rFVIIa)FDA Link
6. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
7. Tranexamic Acid (AMCA)FDA Link
8. Clopidogrel (Plavix)FDA Link
9. Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
08/01/2004 - "In very high-risk patients, a higher dose of LMWH may offer increased efficacy without increasing bleeding risk. "
10/01/2003 - "However the optimal LMWH regimen, offering the greatest efficacy with an acceptable risk of bleeding, has not been clearly established with regard to dose and timing of treatment initiation. "
01/01/2019 - " the primary outcome, the incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control group compared to 5.3% in the patients receiving out-of-hospital LMWH (Mantel Haentzel (M-H) odds ratio (OR) 0.38, 95% confidence interval (CI) 0.26 to 0.54; I2 = 28%; moderate-quality evidence).For the secondary outcome of all DVT, seven studies, n = 1728, showed prolonged thromboprophylaxis with LMWH to be associated with a statistically significant reduction in the incidence of all DVT (M-H OR 0.39, 95% CI 0.27 to 0.55; I2 = 28%; moderate-quality evidence).We found a similar reduction when analysis was limited to incidence in proximal DVT (M-H OR 0.22, 95% CI 0.10 to 0.47; I2 = 0%; moderate-quality evidence).The incidence of symptomatic VTE was also reduced from 1.0% in the control group to 0.1% in patients receiving prolonged thromboprophylaxis, which approached significance (M-H OR 0.30, 95% CI 0.08 to 1.11; I2 = 0%; moderate-quality evidence).No difference in the incidence of bleeding between the control and LMWH group was found, 2.8% and 3.4%, respectively (M-H OR 1.10, 95% CI 0.67 to 1.81; I2 = 0%; moderate-quality evidence).No difference in mortality between the control and LMWH group was found, 3.8% and 3.9%, respectively (M-H OR 1.15, 95% CI 0.72 to 1.84; moderate-quality evidence).Estimates of heterogeneity ranged between 0% and 28% depending on the analysis, suggesting low or unimportant heterogeneity. "
01/01/2019 - " the primary outcome, the incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control group compared to 5.3% in the patients receiving out-of-hospital LMWH (Mantel Haentzel (M-H) odds ratio (OR) 0.38, 95% confidence interval (CI) 0.26 to 0.54; I2 = 28%; moderate-quality evidence).For the secondary outcome of all DVT, seven studies, n = 1728, showed prolonged thromboprophylaxis with LMWH to be associated with a statistically significant reduction in the incidence of all DVT (M-H OR 0.39, 95% CI 0.27 to 0.55; I2 = 28%; moderate-quality evidence).We found a similar reduction when analysis was limited to incidence in proximal DVT (M-H OR 0.22, 95% CI 0.10 to 0.47; I2 = 0%; moderate-quality evidence).The incidence of symptomatic VTE was also reduced from 1.0% in the control group to 0.1% in patients receiving prolonged thromboprophylaxis (M-H OR 0.30, 95% CI 0.08 to 1.11; I2 = 0%; moderate-quality evidence).No difference in the incidence of bleeding between the control and LMWH group was found, 2.8% and 3.4%, respectively (M-H OR 1.10, 95% CI 0.67 to 1.81; I2 = 0%; moderate-quality evidence).No difference in mortality between the control and LMWH group was found, 3.8% and 3.9%, respectively (M-H OR 1.15, 95% CI 0.72 to 1.84; moderate-quality evidence).Estimates of heterogeneity ranged between 0% and 28% depending on the analysis, suggesting low or unimportant heterogeneity. "
11/27/2018 - " the primary outcome, the incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control group compared to 5.3% in the patients receiving out-of-hospital LMWH (Mantel Haentzel (M-H) odds ratio (OR) 0.38, 95% confidence interval (CI) 0.26 to 0.54; I2 = 28%; seven studies, n = 1728; moderate-quality evidence).For the secondary outcome of all DVT, seven studies, n = 1728, showed prolonged thromboprophylaxis with LMWH to be associated with a statistically significant reduction in the incidence of all DVT (M-H OR 0.39, 95% CI 0.27 to 0.55; I2 = 28%; moderate-quality evidence).We found a similar reduction when analysis was limited to incidence in proximal DVT (M-H OR 0.22, 95% CI 0.10 to 0.47; I2 = 0%; moderate-quality evidence).The incidence of symptomatic VTE was also reduced from 1.0% in the control group to 0.1% in patients receiving prolonged thromboprophylaxis (M-H OR 0.30, 95% CI 0.08 to 1.11; I2 = 0%; moderate-quality evidence).No difference in the incidence of bleeding between the control and LMWH group was found, 2.8% and 3.4%, respectively (HM-H OR 1.10, 95% CI 0.67 to 1.81; I2 = 0%; seven studies, n = 2239; moderate-quality evidence).Estimates of heterogeneity ranged between 0% and 28% depending on the analysis, suggesting low or unimportant heterogeneity. "
10. RivaroxabanIBA

Therapies and Procedures

1. Therapeutics
2. Sclerotherapy
3. Ligation
4. Resuscitation
5. Stents